Clinical Trials | CCTG-PR26: A Randomized Phase III Clinical Trial For The Addition Of Docetaxel To Androgen Receptor Pathway Inhibitors In Patients With Metastatic Castration Sensitive Prostate Cancer And Suboptimal PSA Response (TRIPLE-SWITCH)

The University of Virginia Comprehensive Cancer Center seeks participants ages 18 and over with metastatic castration sensitive prostate cancer (mCSPC) who have a suboptimal PSA response after 6-12 months of androgen-targeting therapy. The purpose of this study is to compare overall survival (OS) in participants with mCSPC who are receiving standard of care Androgen Deprivation Therapy (ADT) (between 6-12 months exposure) + Androgen-Receptor Pathway Inhibitor (ARPI) (= 4-months exposure) and have suboptimal PSA response (PSA =0.2 ng/ml at enrollment) with those who receive standard of care ADT + ARPI plus docetaxel chemotherapy. In this study, you will either continue hormone treatment with ADT and ARPI, or you will get docetaxel every 21 days for 6 cycles in addition to hormone treatment with ADT and ARPI, until your disease is no longer responding or the side effects become too severe. You may or may not benefit as a result of your participation in this study. However, this study may also help doctors learn things that can help other people in the future. After you finish your study treatment, your doctor will continue to follow your condition for the rest of your life and watch you for side effects. They will check you every 12 weeks after treatment in clinic or by phone for the rest of your life to monitor your status. Additional information found here: https://clinicaltrials.gov/study/NCT06592924 For questions, contact: [email protected]